Compare Summit Therapeutics Inc (SMMT) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Wolfspeed Inc — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while Wolfspeed Inc trades at $31.89 (market cap $1.53B). The key difference: Summit Therapeutics Inc is far larger — about 6.8× Wolfspeed Inc's market cap, and Wolfspeed Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | WOLF | |
|---|---|---|
Market Cap | $10.48B | $1.53B |
Sector | Health | Technology |
52-Week High | $29.32 | $73.68 |
52-Week Low | $13.05 | $1.19 |
Enterprise Value | $9.90B | $2.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Wolfspeed (WOLF) trades at $29.38, down 1.71% on the day, with a bearish technical outlook driven by moving averages but oversold RSI readings. The company shows negative profitability metrics, including a gross margin of -26.63% and net income margin of -79.83%, though it beat EPS estimates in two of the last three quarters. Recent news highlights strategic moves into data centers and defense, alongside a patent lawsuit against Navitas Semiconductor.
The outlook is mixed, with analyst consensus leaning neutral (47
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
